Cytokines produced during infection/inflammation activate adaptive central nervous system (CNS) responses, including acute stress responses mediated by the hypothalamo-pituitary-adrenal (HPA) axis. The mechanisms by which cytokines engage HPA control circuitry remain unclear, though stimulated release of prostanoids from neighboring vascular cells has been implicated in this regard. How specific vascular cell types, endothelial cells (ECs) versus perivascular cells (PVCs; a subset of brain-resident macrophages), participate in this response remains unsettled. We exploited the phagocytic activity of PVCs to deplete them in rats by central injection of a liposome-encapsulated proapoptotic drug. This manipulation abrogated CNS and hormonal indices of HPA activation under immune challenge conditions (interleukin-1) that activated prostanoid synthesis only in PVCs, while enhancing these responses to stimuli (lipopolysaccharide) that engaged prostanoid production by ECs as well. Thus, PVCs provide both prostanoid-mediated drive to the HPA axis and an anti-inflammatory action that constrains endothelial and overall CNS responses to inflammatory insults.
INTRODUCTION
Episodes of systemic infection or inflammation engage the innate immune system to release proinflammatory cytokines that act on the brain to initiate specific central nervous system (CNS) responses. These include a constellation of acute phase reactions, including somnolence, fever, lethargy, anorexia, and metabolic effects (Hart, 1988; Konsman et al., 2002) , which facilitate adaptation to the challenge at hand. Such insults can also impact the brain's intrinsic immune effector mechanisms, notably microglia, to precipitate or exacerbate a host of neurodegenerative disorders (Choi et al., 2009; Phillis et al., 2006) . Clarifying the cellular-molecular mechanisms of immune-tobrain communication thus has implications not only for understanding basic central processes involved in coping with acute illness but also for identifying targets for intervention in neurological disease.
Here we focus on one key acute phase response system, the hypothalamo-pituitary-adrenal (HPA) axis, an integral part of the brain's stress response machinery (Turnbull and Rivier, 1999; van der Meer et al., 1996) . Glucocorticoid mediators of HPA function exert catabolic effects that mobilize energy reserves to facilitate coping with inflammatory insults and powerfully suppress immune-inflammatory reactions. This latter effect plays a critical regulatory role in preventing excess cytokine production and immune cell proliferation (Webster et al., 2002) . Dysfunction of the central arm of this feedback loop is implicated in the genesis of autoimmune disorders in susceptible animal models (Harbuz et al., 1997) and in humans (Wick et al., 1993) .
The mechanisms by which immune stimuli impact the brain to engage the HPA axis remain unsettled. Multiple routes of access have been supported, whose involvement may vary with the strength and nature of the insult (Dantzer and Kelley, 2007; Quan, 2008) . For stimuli involving intravenous administration of individual proinflammatory cytokines (interleukin-1 [IL-1]) or pathogen analogs (bacterial lipopolysaccharide [LPS] ), which model systemic infection, substantial evidence indicates that circulating cytokines can be monitored by non-neuronal cells of the cerebral vasculature, which appear capable of engaging proximate afferent projections to relevant effector neurons by releasing local signaling molecules, notably prostaglandin E 2 (PGE 2 ; Elmquist et al., 1997; Schiltz and Sawchenko, 2003) . In the case of HPA control circuitry, evidence supports a role for PGE 2 acting on brainstem catecholaminergic neurons that project to corticotropin-releasing factor (CRF)-expressing hypothalamic neurosecretory cells in initiating IL-1-or LPS-stimulated drive on the axis (Ericsson et al., 1994 (Ericsson et al., , 1997 Schiltz and Sawchenko, 2007; van der Meer et al., 1996) .
Questions remain as to the manner and extent to which inducible prostaglandin-dependent mechanisms within the brain contribute to HPA responses and the identity of the vascular cell type(s) involved in transducing immune signals and mounting prostanoid responses. Endothelial cells (ECs) of the cerebral vasculature are optimally positioned to record circulating immune signals, but their threshold to inducible cyclooxygenase (COX-2) expression is high (Schiltz and Sawchenko, 2002) . Perivascular cells (PVCs), a subset of brain-resident macrophages, are more sensitive to COX-2 induction (Schiltz and Sawchenko, 2002) , but their position in the perivascular space between the EC basement membrane and the glia limitans (Thomas, 1999; Williams et al., 2001 ) makes them unlikely to be accessed directly by blood-borne cytokines.
To address these issues, we used a method that exploits the phagocytic capabilities of PVCs to selectively deplete them by central administration of a liposome-encapsulated drug, clodronate (Polfliet et al., 2001b) . The results support a prominent and selective involvement of brain macrophages and their capacity to mount prostanoid responses in immune challenge-induced HPA activation. They also identify a novel, anti-inflammatory influence of this cell type in restraining endothelial involvement in CNS host-defense responses to inflammatory insults.
RESULTS

Liposome-Mediated Targeting of Brain Macrophages
We sought first to validate a method (Polfliet et al., 2001b ) that exploits the phagocytic activity of PVCs and meningeal macrophages (MMs) to selectively deplete them by i.c.v. injection of liposome-encapsulated clodronate. Clodronate is a bisphosphonate drug used to treat osteolytic disease, which can cause irreversible metabolic damage and apoptosis at high intracellular concentrations (Van Rooijen and Sanders, 1994) . Liposomes were labeled with the fluorophore DiI to allow visualization of cells that have incorporated them (Polfliet et al., 2001b) . Injection of control liposomes encapsulating PBS (PBS-Lips) resulted in selective DiI labeling of meningeal and vascular cells that expressed the ED2 macrophage differentiation antigen, a definitive PVC/MM marker (Dijkstra et al., 1985;  Figure 1 ). Using clodronate liposomes (Clod-Lips), ED2-positive cells were frankly reduced in rats sacrificed at 2-3 days and virtually absent in animals killed 5-7 days after injection.
The effectiveness of liposome-mediated targeting of brain macrophages was evaluated after each experiment by costaining series of brain sections for ED2, challenge-induced COX-2 expression, and/or the DiI fluorophore. Rats killed 5-7 days after i.c.v. injection of PBS-Lips and i.v. injection of vehicle displayed DiI labeling strictly limited to ED2-stained cells associated with the meninges and cerebral vasculature. The efficiency of labeling was high, with >95% of all ED2-positive cells colabeled for DiI in samplings from multiple brain regions (see Experimental Procedures). COX-2 was not detected in DiI-and/or ED2-stained cells of control animals. In separate series of sections prepared for concurrent localization of DiI and Iba1, a marker that labels microglia, as well as PVCs/MMs, we failed to detect DiI labeling of parenchymal microglia in any experiment (data not shown).
Rats that received i.c.v. injection of control liposomes and were challenged 7 days later with IL-1 (2 mg/kg, i.v.) displayed a similar disposition of DiI/ED2 labeling, which was overlain by induced COX-2 expression. Vascular and meningeal COX-2 immunoreactivity was strictly confined to ED2-labeled cells. In contrast, Clod-Lip-treated animals challenged with IL-1 showed in most cases a complete absence of vascular and meningeal labeling for DiI, ED2, and COX-2. In these cases, reliable COX-2 labeling was seen only in neurons (mainly in cortical regions) that express the enzyme constitutively.
Ancillary analyses were carried out to assess the broader impact of central liposome treatment. Electron microscopy (conventional and of ED2-immunolabeled material) of brain tissue from control and Clod-Lip-treated rats revealed no major disruption of vascular structure in the latter, save for instances of vacant areas and/or apparent cellular debris in the perivascular spaces, presumably reflecting the loss of ED2+ PVCs (Figure 1 ). Basal laminae and junctions (zonulae occludens) between adjoining ECs appeared unaffected, and there was no evidence of infiltration by circulating lymphocytes. The integrity of the blood-brain barrier was assessed by injecting experimental and control animals i.v. with horseradish peroxidase. Light level analysis of histochemical preparations revealed no detectable penetration of enzyme into the brain parenchyma in either group, aside from that expected at circumventricular organs. Finally, as central injection of Clod-Lips is reported to variably and transiently attenuate peripheral macrophage populations (Polfliet et al., 2001b) , we assessed the most sensitive of these, hepatic Kupffer cells, during the time window (5-7 days postinjection) in which immune challenges were administered ( Figure S1 , available online). Comparisons of the density of ED2-labeled cells in comparable series through the liver of control and Clod-Lip-treated rats (n = 3) revealed no significant difference (p > 0.1).
These observations support the efficacy and selectivity of i.c.v. injection of Clod-Lips in depleting brain-resident vascular and MMs.
Vascular Responses to Immune Insults
Control rats sacrificed 3 hr after IL-1 injection (2 mg/kg, i.v.) displayed the expected induction of COX-2 in the cerebral vasculature and meninges; pretreatment with i.c.v. injection of Clod-Lips 5 days earlier completely eliminated detectable IL-1-induced COX-2 expression at these loci (Figure 2 ). LPS injections (2 mg/kg, i.v.) in PBS-Lip rats provoked the expected COX-2 induction in both multipolar and round vascular profiles shown previously by dual staining to conform to PVCs (ED2+) and ECs (RECA-1+), respectively (Schiltz and Sawchenko, 2002) . Predictably, LPS challenges of Clod-Lip pretreated rats elicited COX-2 responses only in ECs, but this effect was remarkably potentiated in that COX-2-ir ECs were far greater in number (2.4-fold increase) and staining intensity in macrophage-depleted than control rats. Because ECs far outnumber PVCs, the overall density of COX-2-labeled vascular cells in Clod-Lip rats challenged with LPS more than doubled that of PBS-Lip-pretreated controls (Figure 2) .
Analysis of more specific indices of PGE 2 production as function of treatment status yielded generally compatible findings. Thus, vascular expression of microsomal prostaglandin E synthase-1 (mPGES-1), a terminal enzyme in PGE 2 synthesis, which is commonly coupled to COX-2 activity, was not detectable under basal conditions, but was mildly upregulated in response to IL-1 and more strongly in response to LPS in control (PBS-Lip) rats ( Figure S2 ). Concurrent dual localization of mPGES-1 mRNA and ED2-ir indicated that enzyme expression included PVCs in both challenge paradigms, though these were sparse.
Clod-Lip pretreated animals displayed massively potentiated upregulation of mPGES-1 mRNA in presumed ECs following an LPS challenge, consistent with the COX-2 findings in this cell type described above, but this was also seen in IL-1-injected rats, whose endothelia failed to mount a detectable COX-2 response. To determine whether altered expression of prostaglandin biosynthetic enzymes in Clod-Lip pretreated rats is reflected in altered release of PGE 2 , we attempted time course analyses in which prostanoid levels were measured by enzyme immunoassay in extracts of hypothalamus or medulla. This was not feasible in IL-1-challenged animals, as basal and stimulated PGE 2 were below the detection limits of the assay. With LPS, however, Clod-Lip pretreated rats displayed a more rapid, pronounced, and prolonged LPS-induced rise in brain tissue levels of PGE 2 than controls ( Figure 2 ). To overcome the lack of sensitivity in the IL-1 model, we established a protocol for immunolocalization of PGE 2 itself (see Experimental Procedures) and found a clear and discrete upregulation of PGE 2 -ir in identified PVCs of intact rats injected with IL-1; similarly challenged Clod-Lip pretreated animals failed to display detectable prostanoid signals in brain (Figures 2 and S3 ). LPS challenge in control rats also gave rise to detectable PGE 2 immunostaining, which was punctate in appearance and codistributed in part with an endothelial marker. This staining was enhanced in macrophage-depleted rats and, in addition, extended into the parenchyma, with some taking the form of microglial-like cellular profiles, a localization confirmed by costaining with a microglial marker (Iba-1; data not shown).
Overall, the enhanced inducible PGE 2 responses to LPS in the brain macrophage-depleted model indicates that PVCs exert a potent restraining influence on EC activity in transducing circulating immune signals. The starkly differential effects of liposome treatment on multiple indices of PGE 2 production after IL-1 versus LPS challenges define models for evaluating the role of vascular prostanoid synthesis in acute phase responses.
Effects on Central Stress-Related Circuitry
Differences in IL-1-and LPS-induced vascular COX-2 induction in Clod-Lip animals were mirrored in challenge effects on HPA control circuitry, assessed using Fos immunostaining as a generic marker of cellular activation ( Figure 3 ). Projections to the hypothalamus arising from catecholamine-containing (adrenergic and noradrenergic) neurons in the caudal brainstem (nucleus of the solitary tract and ventrolateral medulla) have been specifically implicated in mediating IL-1 and LPS effects on HPA output (Ericsson et al., 1994; Schiltz and Sawchenko, 2007; van der Meer et al., 1996) . Here, we confirmed that both cell groups display markedly increased Fos expression in response to standard doses of IL-1 or LPS (2 mg/kg, i.v.). Costaining for Fos and the catecholamine biosynthetic enzymes dopamine-b-hydroxylase and phenylethanolamine-N-methyltransferase identified the overwhelming majority of responsive neurons as displaying the adrenergic or noradrenergic phenotype ( Figure S4 ). Whereas Clod-Lip pretreatment exerted no discernible effect on Fos expression in saline-injected controls, it resulted in markedly reduced responses to IL-1, to levels that did not differ reliably from those of controls. In contrast, brain macrophage depletion yielded significant increases in the number of NTS and VLM neurons displaying activational responses to LPS, over and above that seen after similar injection in PBS-Lip pretreated animals (p < 0.01).
At the level of hypothalamic effectors that control HPA output, IL-1-induced Fos expression in control rats was focused in the CRF-rich hypophysiotropic zone of the PVH, and this response was reduced (by 80%) in Clod-Lip pretreated animals to levels that did not differ from those of vehicle-injected control animals (p > 0.1). LPS provoked a similarly focused, but more robust, activation of PVH neurons in PBS-Lip rats. Clod-Lip pretreatment resulted in a reliable increase in the number of responsive PVH neurons, attributable to recruitment of cells in the magnocellular division of the nucleus, which have also been implicated as contributing to central drive on the HPA axis (Holmes et al., 1986) . This analysis was carried out in material prepared under staining conditions that optimize sensitivity of immunolocalization, and the robustness of LPS-induced Fos in the parvocellular neurosecretory zone of the PVH might impose a ceiling effect. Staining of additional series of sections from control and ClodLip animals challenged with LPS using higher dilutions of Fos antiserum revealed a reliable (31%) increase in the number of labeled cells in the parvocellular PVH, supporting the contention that macrophage depletion results in enhanced drive to both major functional compartments of the nucleus. This finding was further supported by comparisons of relative levels of CRF mRNA in the PVH, which revealed a reliably greater increase in the Clod-Lip (2.2-fold) than PBS-Lip group (1.6-fold) in response to LPS (p < 0.05).
Together, these findings indicate that brain macrophages are required for IL-1 engagement of HPA control circuitry, which at both medullary and hypothalamic levels responds to brain macrophage depletion in a manner indicative of a positive relationship with vascular COX-2/PGE 2 production. This extends to the exaggerated HPA-regulatory responses seen in the LPS model.
Stress Hormone Secretion
To determine whether altered responsiveness of HPA control circuitry as a function of brain macrophage status is mirrored by changes in hormonal output, separate groups of rats (n = 5) pretreated with control or Clod-Lips were implanted with jugular catheters and challenged 2 days later with IL-1 or LPS as above, and repeated blood samples were collected for radioimmunoassay of plasma adrenocorticotropic hormone (ACTH) and corticosterone. Basal titers of neither hormone varied reliably as a function of brain macrophage status (Ps > 0.1; Figure 4 ). An IL-1 challenge elicited rapid and reliable increases in plasma levels of both hormones that peaked at similar time points. However, both the ACTH and corticosterone secretory responses of Clod-Lip-treated rats were of significantly lesser magnitude and duration than those of control animals. Total integrated responses, as assessed by calculating areas under the curve (AUC), were reduced to 49% (ACTH) and 37% (corticosterone) of control values (Ps < 0.001).
LPS also elicited significant increases in ACTH and corticosterone secretion in both groups that peaked at similar time points, and in the case of corticosterone achieved similar maxima (Figure 4 ). But the magnitude of peak ACTH titers and the duration of both hormonal responses were substantially greater in Clod-Lip-treated rats, as were AUC measures (2.4-and 1.5-fold increases for ACTH and corticosterone, respectively; Ps < 0.001). Thus, the differential effects of brain macrophage depletion on IL-1-and LPS-driven engagement of HPA control circuitry are predictive of alterations in stress hormone secretion. Other Acute Phase Responses Groups of rats (n = 9) pretreated centrally with clodronate or control liposomes were implanted with telemetry transducers to allow continuous remote monitoring of body temperature and locomotor activity. Two days later, they were challenged with IL-1 or LPS 1 hr prior to the onset of the nocturnal phase of the lighting cycle, when animals are most active. In rats pretreated with control liposomes, IL-1 elicited a biphasic core temperature response, with an initial mild hypothermia preceding a more substantial fever that peaked at $2 hr after injection ( Figure 5 ). Clod-Lip treated animals failed to exhibit a significant decline in core temperature, but the peak magnitude of their febrile responses did not differ reliably from those of controls. LPS provoked in both groups an early rise and decline in core temperature, whose timing and magnitude were similar. Thereafter, controls exhibited a biphasic rise in temperature with peaks at roughly 2.75 and 6 hr after injection, whereas brain macrophage-depleted rats displayed a monophasic fever that peaked at $6 hr and whose magnitude was significantly greater over the 3.5-4.5 hr time interval (Ps < 0.05).
In contrast, activity responses were unaffected by Clod-Lip pretreatment. Both IL-1 and LPS treatments ( Figure 5 ) gave rise to rapid and significant (Ps < 0.01) decrements in activity beginning at 0.5-1.5 hr after injection, and their magnitude did not differ reliably as a function of brain macrophage status at any time point through 6 hr after injection (Ps > 0.10; Figure 5 ).
Repetition of this study in separate groups challenged with IL-1 or LPS during the subjective morning hours yielded compatible results ( Figure S5 ).
DISCUSSION
Differential effects of brain macrophage ablation on indices of cerebrovascular PGE 2 production induced by IL-1 (reduced) versus LPS (exaggerated) were paralleled by altered responses of the HPA axis and its CNS control circuitry. Other acute phase responses were affected less profoundly (fever) or not at all (lethargy). The results support a dependence of HPA responses to proinflammatory insults on the integrity of PVCs and their capacity to mount prostanoid responses and define a novel anti-inflammatory interaction between perivascular cells and ECs in transducing circulating cytokine signals and sculpting specific CNS responses to them.
Model and Implications
A model to summarize these findings is provided in Figure 6 . In response to IL-1, the circulating cytokine activates PVCs most likely indirectly, after first being bound by endothelial type 1 IL-1 receptors (Ericsson et al., 1995) . ECs are responsive to this stimulus and signaling through them is required for upstream CNS effects (Ching et al., 2007; Gosselin and Rivest, 2008 ), but they do not display detectable indices of PGE 2 production, due at least partly to a restraining influence exerted on them by PVCs. PVC activation leads to production and release of PGE 2 , which acts in a paracrine manner to engage HPA control circuitry and, consequently, its effector arm in the endocrine hypothalamus. Accordingly, elimination of PVCs abrogates vascular PGE 2 production and the HPA response. Moderate to high doses of LPS engage PVCs in a similar manner and are able to partially overcome the PVC-imposed brake, leading to endothelial PGE 2 synthesis and a greater total vascular prostanoid response. PVC ablation removes the brake, leading to further enhancement of EC and overall PGE 2 production, and its effects are manifest particularly during the later stages of HPA and febrile responses.
The immune challenge parameters used here were chosen based on their ability to elicit vascular COX-2 responses exclusively from PVCs (IL-1) or from both these and ECs (LPS; Schiltz and Sawchenko, 2002) . Bolus administration of IL-1 is an admittedly artificial situation, but presents a discrete stimulus that mimics many CNS effects of systemic infection (Dinarello, 1991) . LPS is a component of the cell wall of gram-negative bacteria and is widely used to model infection or sepsis (Ulevitch and Tobias, 1995) . It stimulates the release of several proinflammatory cytokines, prominently including IL-1 (Turnbull and Rivier, 1999) , and can also act directly by binding a toll-like receptor 4/MD2/CD14 complex (Laflamme and Rivest, 2001 ). Importantly, like IL-1, low doses of LPS stimulate COX-2 only in PVCs (Schiltz and Sawchenko, 2002) and we would predict that results obtained in the IL-1 model would generalize to mild LPS challenges.
These findings clarify the cellular mechanisms by which challenges that model systemic infection access the brain to engage specific CNS response systems, notably HPA axis activation and fever, that facilitate coping with insult. Glucocorticoid mediators of HPA function serve to mobilize energy reserves and constrain systemic immune responses, while fever may create a suboptimal thermal environment for pathogen proliferation and can directly enhance certain host defense mechanisms (Mackowiak, 1998) .
Understanding the transit of immune signals across the bloodbrain barrier also has implications for the many neurodegenerative diseases in which central inflammatory mechanisms are believed to play a contributing role. Systemic LPS and/or IL-1 treatment is commonly reported to exacerbate neuropathology and cognitive/behavioral symptoms in animal models of Alzheimer's, Parkinson's and Prion diseases and ALS (Byler et al., 2009; Cunningham et al., 2005; Kitazawa et al., 2005; Letiembre et al., 2009) . A single (high) dose of LPS, alone, can cause persistent CNS inflammation and neuronal loss (Qin et al., 2007) . Moreover, animals challenged neonatally with IL-1 or LPS display altered central regulation of the HPA axis that persists into adulthood (Shanks et al., 1995) and may predispose individuals to an even broader array of stress-related pathologies. In this light, the identification of a potent anti-inflammatory mechanism at the blood-brain interface should provide leverage in identifying targets for intervention in a range of pathologies. The liposome-targeting approach used here has been shown not detectable in either vascular cell type. In intact rats, IL-1 provokes robust cytoplasmic PGE 2 staining localized discretely to PVCs, while cytokine-induced labeling is absent in PVC-depleted animals. LPS induces more widespread punctate PGE 2 staining, a portion of which localizes to ECs; this labeling is enhanced in Clod-Lip-pretreated animals. Scale bars: 100 mm. Brightfield images of IL-1-and LPS-induced Fos expression in the ventrolateral medulla (top) and PVH (middle) as a function of brain macrophage status. Histograms show mean ± SEM number of cells in the A1 and C1 regions of the ventrolateral medulla and PVH in each condition (n = 5-7 per group). Liposome treatment did not significantly affect basal levels of Fos expression in either region, and data from PBS-and Clod-Lip rats that received i.v. saline injections are pooled for presentation. Clod-Lip treatment reduced IL-1 stimulated Fos expression in medullary neurons whose projections are required for HPA activation and their hypothalamic targets in the parvocellular part of PVH (mp; outlined in blue) that governs HPA output. In contrast, brain macrophage depletion enhanced activational responses induced by LPS at both levels of the HPA control circuit. This includes recruitment of additional cell types in the magnocellular division of the nucleus (pm; outlined in red). (Bottom) Darkfield photomicrographs showing CRF mRNA under basal (saline-injected) and 3 hr after LPS challenge in control and Clod-Lip-injected rats. Mean ± SEM relative levels of this transcript in these treatment groups (n = 5-8) are shown. Clod-Lip pretreated rats display significantly enhanced upregulation of CRF mRNA, relative to similarly challenged rats that received control liposome injections. *p < 0.05; **p < 0.01 versus saline-injected controls. Scale bars: 100 mm.
to modulate disease progression in animal models of multiple sclerosis, meningitis, and Alzheimer's disease (Hawkes and McLaurin, 2009; Polfliet et al., 2001a Polfliet et al., , 2002 and the feasibility of using the stem cells that give rise to them as vehicles for gene therapy has been established (Hahn et al., 1998; Priller et al., 2001 ).
What Are Perivascular Cells? Along with MMs, PVCs are derived from bone marrow precursors that populate the brain in early postnatal life and turn over slowly throughout adulthood (Bechmann et al., 2001a; Vallieres and Sawchenko, 2003) . They are distinct from pericytes and parenchymal microglia, though they may share a common lineage with them (Gehrmann et al., 1995; Thomas, 1999) . As shown in the present study, PVCs are constitutively phagocytic, with their definitive ED2 marker having been identified as a macrophage scavenger receptor, CD163 (Fabriek et al., 2007) . PVCs can serve as antigen-presenting cells (Hickey and Kimura, 1988) , participate in the immune surveillance of the nervous system (Bechmann et al., 2001b; Hickey, 2001) , and have been implicated in a host of pathological processes, including the entry of HIV into the nervous system (Stoll and Jander, 1999; Thomas, 1999) .
Prostaglandin Involvement in CNS Host Defense PGE 2 levels in brain are increased following systemic IL-1 or LPS injection (Dinarello, 1991; Sehic et al., 1996) , and a wealth of evidence indicates that central or peripheral blockade of prostanoid synthesis using COX inhibitors (NSAIDs) can disrupt the HPA activation normally elicited by these challenges (Ericsson et Mean ± SEM plasma ACTH (top) and corticosterone (CORT; bottom) levels in control rats (black) and animals pretreated with Clod-Lips (red) and subsequently challenged with i.v. injection of 3 mg/kg IL-1 (left) or 2 mg/kg LPS (right). In IL-1-challenged rats, macrophage ablation did not affect the timing of peak ACTH and CORT responses, but attenuated their magnitude, and markedly reduced the time over which significant elevations were observed. Conversely, and in line with the COX-2 and Fos data, the principal effect of Clod-Lip pretreatment in LPS-challenged rats was to significantly enhance the longevity of hormonal responses. n = 5-6 per group. *, differs significantly from control liposome group, p < 0.05; **p < 0.01; ***p < 0.001. Watanabe et al., 1990) . The cellular sources of central prostaglandin production have remained a major point of contention, with previous reports being divided as to whether PVCs (Elmquist et al., 1997; Schiltz and Sawchenko, 2002) or ECs (Cao et al., 1996; Matsumura et al., 1998; Quan et al., 1998) are the dominant seats of LPS-and/or IL-1-driven vascular COX-2 induction. We offered a potential reconciliation by identifying PVCs as the sole site of COX-2 expression following IL-1 or low doses of LPS, with endothelia recruited at higher endotoxin doses (Schiltz and Sawchenko, 2002) .
Multiple indices of IL-1-driven HPA activity were suppressed in brain macrophage-depleted rats, supporting a prominent role for PVCs in the activation of central stress circuitry and hormone secretion under this condition. As IL-1 is the most potent of the proinflammatory cytokines induced by LPS in stimulating HPA output (Turnbull and Rivier, 1999) , we conclude that PVCs provide a generalized, low-threshold impetus for the engagement of this system by infection/inflammation. Hormonal responses to IL-1 were not completely eliminated by central macrophage depletion, leaving open possible contributions of adjunct central or peripheral mechanisms. Direct IL-1 actions on the pituitary and adrenal glands to stimulate ACTH and corticosterone secretion, respectively, have been described (Bernton et al., 1987; Engstrom et al., 2008) .
In addition to indicating a requirement for PVCs in IL-1-induced HPA activation, our findings are also consistent with COX-dependent PGE 2 production in mediating this influence. PGE 2 production from the COX-dependent intermediate PGH 2 may be catalyzed by several terminal PGE 2 synthases, with mPGES-1 being commonly coupled to COX-2 activity (Ivanov and Romanovsky, 2004 ). While we found that vascular mPGES-1 expression co-varied directly with COX-2, PGE 2 , and HPA-related endpoints across most treatment conditions, it was expressed only weakly in PVCs of IL-1-stimulated rats. This raises the question of how PGE 2 is generated in this cell type with the alacrity Neuron Vascular Mediation of Inflammatory Effects on CNS required of acute phase mechanisms. There are recent data to implicate the constitutively expressed cyclooxygenase isoform COX-1 in the initial phase of LPS-induced HPA activation (Elander et al., 2009; Garcia-Bueno et al., 2009; Zhang et al., 2003) . New findings that COX-1 is expressed under basal conditions by PVCs and microglia, and is LPS-inducible in endothelia (Garcia-Bueno et al., 2009) , are consistent with a role in the present context. It remains to be determined whether other PGE 2 synthases, notably COX-1-associated cytosolic PGES, are positioned to support COX-1 involvement. Figure 5 . Liposome Effects on IL-1-and LPS-Induced Fever and Lethargy (Left) Mean ± SEM change in core body temperature (Tc; data points in 3 min bins) of rats pretreated with control (black) or Clod-Lips (red) and challenged (arrowhead) with i.v. injection of IL-1 (top) or LPS (bottom) 1 hr before lights out. Brain macrophage ablation eliminated an early hypothermic response to IL-1, but did not significantly affect the magnitude or duration of subsequent fever. In contrast, LPS-induced fever was enhanced at 3.5-4.5 hr after injection. (Right) Locomotor activity data (averaged into 30 min bins) from the same animals. Clod-Lip treatment did not affect the hypoactivity elicited by either treatment. n = 9 per group. *, differs significantly from control liposome group, p < 0.05. Involvement of PGE 2 , itself, in CNS responses to inflammatory stimuli is commonly inferred on the basis of COX-2 expression. Here, we provide biochemical/histochemical data supporting discrete PGE 2 induction in PVCs after IL-1 treatment, more broadly in response to LPS, and for regulation in step with HPA endpoints in macrophage-depleted rats. This evidence is correlative, and it must be noted that PGE 2 is one of several prostanoids whose levels increase in brain following insults of the kind we used (Choi et al., 2008; de Vries et al., 1995) . Supporting specific involvement of PGE 2 are the findings that IL-1 activates medullary catecholaminergic neurons that express EP3 (and inducible EP4) PGE 2 receptors (Ek et al., 2000) and that microinjection of PGE 2 into these cell groups discretely activates them and their hypothalamic targets that govern HPA output in a manner closely mimicking the response to systemic immune challenge (Ericsson et al., 1997) . In addition, genetic deletion of PGE 2 receptor subtypes (EP1 and EP3) attenuates HPA responses to LPS (Matsuoka et al., 2003) .
Response Specificity of PVC Involvement
The disruptive effect of brain macrophage depletion on IL-1-induced HPA activation did not generalize to other acute phase responses. The body temperature profile was not affected, save for an attenuation of an early hypothermic response. In contrast, later phases of LPS-induced fever (stages 2-3 in the terminology of Romanovsky et al. [2005] ) were enhanced. The timing of this effect correlates well with observed elevations in endothelial COX-2, mPGES-1 expression, and PGE 2 levels in Clod-Liptreated rats, again reflecting PVC-imposed restraint of endothelial PGE 2 production. Our failure to detect any effect of brain macrophage depletion on IL-1-or LPS-induced reductions in locomotor activity is consistent with reports that COX inhibitors affect this response subtly, if at all (Otterness et al., 1991; Wieczorek and Dunn, 2006) . Overall, the results indicate differential involvement of the mechanisms we describe in acute phase responses.
Perivascular-Endothelial Cell Interactions
The shift in the EC COX-2/PGE 2 production that we describe following ablation of an adjacent cell type (PVCs) has an intriguing parallel in recent work on cardiac myocytes and fibroblasts (Wang et al., 2009) . In the present case, the throttling influence of PVCs is also evident using more generic markers of EC activation, including the vascular early response gene Verge and components of the nuclear factor-kB signaling pathway (J.S. and P.E.S., unpublished data). In view of the potential for exploiting this mechanism to intervene in inflammatory CNS disease, its molecular underpinnings are of particular interest. One candidate for fulfilling such a role is nitric oxide; its expression can be induced by LPS or IL-1 in a number of tissue macrophage populations and cerebrovascular elements (Wong et al., 1996a (Wong et al., , 1996b and it can inhibit cytokine-stimulated endothelial COX-2 expression (Blais and Rivest, 2001) , as well as HPA activation (Turnbull and Rivier, 1999) . Another potential mediator is 15-deoxy D 12,14 prostaglandin J 2 (15d-PGJ 2 ), an alternate COX-dependent prostanoid product. 15d-PGJ 2 has been shown capable of suppressing LPS-induced COX-2 synthesis by serving as an endogenous ligand for the peroxisome proliferator-activated receptor-g (PPARg) and/or by direct interference with nuclear factor-kB signaling pathway, both of which are present and active in the vascular endothelium (Bianchi et al., 2005; Inoue et al., 2000; Simonin et al., 2002) . Inhibitory effects of 15d-PGJ 2 on LPS-induced fever have been described (Mouihate et al., 2004) , though it remains unclear whether this or other PPARg ligands are produced in meaningful concentrations in the cellular context of interest here.
Concluding Remarks
The results indicate dual, time-dependent roles of brain resident macrophages in CNS responses to inflammatory insults. These cells are required for full manifestation of HPA responses to IL-1 challenge, and this requirement exhibits acute phase response specificity. This same cell type serves normally to restrain endothelial prostanoid production; in its absence, the latter stages of HPA and febrile responses to LPS are enhanced. Across conditions, HPA and febrile responses co-varied closely with overall vascular COX-2/PGE 2 expression, supporting a dynamic, prostanoid-based transduction mechanism at the brain-vascular interface. Further elaboration of this interplay is expected to clarify central mechanisms of adaptation to acute sickness and to provide leverage in the many CNS disease states in which inflammatory mechanisms are involved.
EXPERIMENTAL PROCEDURES Animals
Adult male Sprague-Dawley albino rats (260-340 g) were housed under standard vivarium conditions with food and water freely available and were adapted to handling for at least 5 days prior to manipulation. All protocols were approved by the Institutional Animal Care and Use Committee of the Salk Institute.
Liposome Preparation and Delivery
Liposomes were prepared as previously described (Van Rooijen and Sanders, 1994) . These are polylamellar phosphatidylcholine-cholesterol membranes that encapsulate clodronate (used at a concentration of 250 mg/ml), are mannosylated to facilitate receptor-mediated uptake, and are labeled with carbocyanine dye DiI (D282; Molecular Probes) to enable detection of cells that have incorporated them. For i.c.v. injection, rats were anesthetized with ketaminexylazine-acepromazine (25:5:1 mg/kg, s.c.) and mounted in a stereotaxic frame. Control (encapsulating PBS) or clodronate-liposomes were equilibrated to room temperature, gently shaken to resuspend them, and injected in a volume of 50 ml over 10 min into a lateral ventricle using a 26 gauge needle mounted onto a stereotaxic arm and attached via PE tubing to a 1000 ml gastight syringe (Bee Stinger, BAS). Rats were allowed 5-7 days to recover prior to testing, the point at which depletion of brain macrophages is maximal, and prior to repopulation by bone marrow-derived progenitors (Polfliet et al., 2001b; Van Rooijen and Sanders, 1994) .
Intravenous Administration of IL-1b and LPS
Indwelling jugular catheters (PE 50) containing sterile, heparin-saline (50 U/ml) were implanted under isoflurane anesthesia (Ericsson et al., 1994) . After 2 days recovery, awake and freely moving rats were injected with 2 mg/kg of recombinant rat IL-1b (provided by R. Hart, Rutgers University) or its vehicle (1 ml/kg, 0.01% BSA, 0.01% ascorbic acid, 10 mM Tris-HCl, and 36 mM sodium phosphate buffer [pH 7.4] ) and returned to their home cages. In similar experiments, groups of rats were injected with LPS from E. coli at 2.0 mg/kg (Sigma-Aldrich; serotype 055:B5) or sterile saline (1 ml/kg).
Perfusion and Histology
At appropriate time points (2-4 hr after injection), rats were anesthetized and perfused via the ascending aorta with 4% paraformaldehyde in borate buffer (pH 8.0) at 4 C and the brains were removed, postfixed for 3 hr, and cryoprotected overnight. Regularly spaced series of coronal sections (30 mm thick) were collected in cryoprotectant solution and stored at À20 C until processing.
Immunohistochemistry
Immunolocalization was achieved using conventional avidin-biotin immunoperoxidase (Vectastain Elite kit; Vector Laboratories) and dual indirect immunofluorescence methods (Sawchenko et al., 1990) , the latter employing fluorescein-, Cy5-, and/or Alexa 488-conjugated secondary antisera (Molecular Probes). Combined immunoperoxidase staining with dual fluorescence or with in situ hybridization was carried out using protocols described previously (Chan et al., 1993; Ericsson et al., 1994) . Descriptions of all but one of the antisera used are provided as Supplemental Experimental Procedures. To localize PGE 2 -ir, a rabbit polyclonal antiserum raised against PGE 2 (Oxford Biomedical Research) was used. This serum recognizes PGE 2 and associated pathway-specific arachidonate derivatives, including PGE 1 , PGA 2 , and PGB 2 , but does not cross-react with other prostanoids. After screening a range of fixation protocols in sections from rat tissues that express PGE 2 constitutively (kidney and gut) and the brains of IL-1-or LPS-treated animals, the following yielded the most sensitive and discrete localization in the cerebral vasculature. Rats were rapidly anesthetized and perfused briefly via the ascending aorta with saline (100 ml over $2 min). Brains were then extracted, immersed in ice-cold saline for 1 min, and transected in the coronal plane into forebrain and brainstem blocks, and immersion fixed overnight in 4% paraformaldehyde in borate buffer (pH 9.5) with 15% sucrose added. Adsorption tests were carried out by incubating antiserum overnight in the presence of graded concentrations of PGE 2 (half order of magnitude increments between 2.8 mM and 2.8 mM) prior to application to brain sections from IL-1-or LPS-challenged rats. Concentrations R280 mM abolished all detectable labeling.
Hybridization Histochemistry
Techniques for probe synthesis, hybridization, and autoradiographic localization of mRNA signal were adapted from Simmons et al. (1989) and are detailed as Supplemental Experimental Procedures.
Electron Microscopy These procedures are described as Supplemental Experimental Procedures.
Intravenous HRP Injections
This procedure is described as Supplemental Experimental Procedures.
Stress Hormone Assays
Separate groups of animals were implanted with indwelling jugular catheters 5 days after i.c.v. injection of clodronate or control liposomes and 2 days before stress exposure. Blood samples (300 ml) were taken prior to i.v. injection of IL-1 or LPS at 30 min and then hourly through 6 hr after injection. They were collected into chilled EDTA-containing tubes and centrifuged; plasma was stored at À20 C until assay. ACTH was measured using a two-site immunoradiometric assay obtained in kit form (DiaSorin), with intra-and inter-assay coefficients of variation of 3% and 9%, respectively, and a sensitivity of 5 pg/ml. Plasma corticosterone was measured without extraction, using an antiserum raised in rabbits against a corticosterone-BSA conjugate and 125 I-corticosterone-BSA as tracer (MP Biomedicals). The sensitivity of the assay was 0.8 mg/dl; intra-and inter-assay coefficients of variation were 5% and 10%, respectively.
PGE 2 Assays
Tissue PGE 2 levels were measured by enzyme immunoassay using reagents in kit form (Prostaglandin E 2 enzyme immunoassay kit-monoclonal; Cayman Chemical Company). Details are given as Supplemental Experimental Procedures.
Telemetry Separate groups of rats received i.c.v. injections of control or Clod-Lips and 5 days later were implanted with jugular catheters for i.v. injection of IL-1, LPS, or their respective vehicles, as described above. Under the same anesthetic dose, telemetry transmitters (Mini-Mitter) were implanted intra-abdominally. Two days later, core body temperature and activity levels were recorded continuously for 24 hr before and after i.v. injection. Transmitter output was monitored by a receiver board beneath the animals' cages, which recorded core temperature (to ±0.1 C) and episodes (counts) of gross horizontal movement.
SUPPLEMENTAL INFORMATION
Supplemental Information includes five figures and Supplemental Experimental Procedures and can be found with this article online at doi:10.1016/ j.neuron.2009.11.032.
